Lesson of the month 1: Sodium valproate-induced encephalopathy
- PMID: 30287443
- PMCID: PMC6334110
- DOI: 10.7861/clinmedicine.18-5-430
Lesson of the month 1: Sodium valproate-induced encephalopathy
Abstract
A 69-year-old man developed reduced consciousness of sudden onset. Examination and parameters were normal, except for a Glasgow Coma Scale (GCS) score of six. Brain imaging and blood tests were also normal, except for high plasma ammonia. His past medical history included epilepsy, hypertension and colitis. He was taking multiple antiepileptic medications, including sodium valproate, with no recent dose alterations. Medical intervention led to the sodium valproate being stopped and naloxone being administered. The patient's level of responsiveness and ammonia levels gradually improved. The patient was also being treated with ciprofloxacin for a urinary tract infection and a newly developed syndrome of inappropriate antidiuretic hormone secretion treated with demeclocycline. There is an association between long-term sodium valproate use and low carnitine levels, especially in the setting of polypharmacy. This in turn precipitates hyperammonaemia and encephalopathy. This case highlights the importance of an adequate drug history and the awareness of serious but uncommon adverse effects.
Keywords: Sodium valproate; encephalopathy; hyperammonaemia; naloxone.
© Royal College of Physicians 2018. All rights reserved.
Similar articles
-
Valproate-induced hyperammonemic encephalopathy treated by L-ornithine-L-aspartate: a case report.Clin Med (Lond). 2023 May;23(3):271-274. doi: 10.7861/clinmed.2023-0137. Clin Med (Lond). 2023. PMID: 37236802 Free PMC article.
-
Sodium valproate-related hyperammonaemic encephalopathy.BMJ Case Rep. 2014 Apr 10;2014:bcr2014203899. doi: 10.1136/bcr-2014-203899. BMJ Case Rep. 2014. PMID: 24722719 Free PMC article.
-
Non-hyperammonaemia valproate-induced encephalopathy: A case report.J Clin Pharm Ther. 2022 Mar;47(3):415-419. doi: 10.1111/jcpt.13511. Epub 2021 Aug 31. J Clin Pharm Ther. 2022. PMID: 34462930
-
[Valproic acid-induced hyperammonemic encephalopathy in a patient receiving valproic acid monotherapy].Rinsho Shinkeigaku. 2019 May 28;59(5):258-263. doi: 10.5692/clinicalneurol.cn-001254. Epub 2019 Apr 26. Rinsho Shinkeigaku. 2019. PMID: 31061301 Review. Japanese.
-
Valproate-induced hyperammonemic encephalopathy in neurosurgical patients: Our experience and systematic literature review.Neurosurg Rev. 2024 Nov 6;47(1):836. doi: 10.1007/s10143-024-03054-z. Neurosurg Rev. 2024. PMID: 39503745
Cited by
-
Endoxifen in Bipolar Disorder With Hyperammonemia and Renal Impairment: A Case Report.Cureus. 2025 Jan 3;17(1):e76839. doi: 10.7759/cureus.76839. eCollection 2025 Jan. Cureus. 2025. PMID: 39897274 Free PMC article.
-
Valproate induced carnitine deficiency and hyperammonaemia.Clin Med (Lond). 2023 Jul;23(4):429. doi: 10.7861/clinmed.Let.23.4.1. Clin Med (Lond). 2023. PMID: 37524421 Free PMC article. No abstract available.
-
Sodium Valproate-Induced Hyperammonemia: A Case Series in a Tertiary Care Hospital.Cureus. 2024 Jul 25;16(7):e65390. doi: 10.7759/cureus.65390. eCollection 2024 Jul. Cureus. 2024. PMID: 39184772 Free PMC article.
References
-
- Carr RB. Shrewsberry K. Hyperammonaemia due to valproic acid in the psychiatric setting. Am J Psychiatry. 2007;164:1020–7. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous